Evidence map›Paper›PMID 30370468›Full record

ArticleRheumatology and therapy2018

Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study.

Boulos Haraoui, Shahin Jamal, Vandana Ahluwalia, Diana Fung, Tarang Manchanda, Majed Khraishi

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01613378 (A Multi-National, Multi-Center Non-Interventional Study in Rheumatoid Arthritis), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01613378 completednot on this map

A Multi-National, Multi-Center Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Who Are Treated With Tocilizumab

TypeobservationalSponsorHoffmann-La RocheRan2012 to 2014Enrolled200ConditionsRheumatoid ArthritisArmsNo intervention
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Boulos HaraouiDepartment of Medicine, Université de Montréal, Montreal, QC, Canada. haraouib@gmail.com.
Shahin JamalDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Vandana AhluwaliaRheumatology Division, William Osler Health System, Brampton, ON, Canada.
Diana FungHoffmann-La Roche Canada, Mississauga, ON, Canada.
Tarang ManchandaHoffmann-La Roche Canada, Mississauga, ON, Canada.
Majed KhraishiFaculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada.
Roche (Canada) · CAMemorial University of Newfoundland · CAUniversité de Montréal · CAUniversity of British Columbia · CAWilliam Osler Health System · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study was conducted to observe patterns of use of the interleukin-6 receptor-alpha inhibitor tocilizumab in routine clinical practice in patients with rheumatoid arthritis (RA).

methodsThis was a 12-month noninterventional, observational study in adult patients with RA who initiated tocilizumab in routine practice in Canada according to the local product monograph. The primary end point was the proportion of patients receiving tocilizumab at 6 months. Secondary end points were treatment patterns, effectiveness, and safety of tocilizumab over 12 months.

resultsOf 200 patients who initiated tocilizumab (91.0% at 8 mg/kg), 67 (33.5%) received tocilizumab monotherapy and 133 (66.5%) received tocilizumab combined with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Kaplan-Meier analysis estimated that 85% (95% CI 74-92%) of monotherapy and 89% (95% CI 82-93%) of combination therapy patients continued to receive tocilizumab at 6 months (log-rank p = 0.0888). During the observation period, 12 (17.9%) monotherapy and 27 (20.3%) combination therapy patients withdrew from the study. At month 12, 58.5% in the monotherapy group and 59.3% in the combination therapy group achieved Disease Activity Score at 28 joints remission (≤ 2.6), 25.6% and 24.7% achieved Simplified Disease Activity Index remission (≤ 3.3), and 18.2% and 22.3% achieved Clinical Disease Activity Index remission (≤ 2.8), respectively. Rates of serious adverse events and serious infections were found in 29.6/100 patient-years (PY) and 3.1/100 PY, respectively, for monotherapy and 19.2/100 PY and 4.8/100 PY, respectively, for combination therapy.

conclusionsPatients initiating tocilizumab in routine practice had comparable effectiveness and safety outcomes regardless of whether they received tocilizumab as monotherapy or as combination therapy with csDMARDs.

trial registrationClinicalTrials.gov identifier, NCT01613378

fundingF. Hoffmann-La Roche (Roche) Canada.

Indexed as

Antirheumatic agentsBiological agentsInflammationInterleukin-6 receptorPrimary careRheumatoid arthritisTocilizumab

Identifiers

PMID30370468
PMCPMC6251854
OpenAlexW2898156360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.